Teva wins generic Lovaza approval

The fish oil medication lowers triglycerides in the blood and prevents heart attacks.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has obtained US Food and Drug Administration (FDA) approval for its generic version of Lovaza, a fish oil medication for lowering triglycerides in the blood. Teva will begin shipping immediately.

Brand Lovaza, sold by GlaxoSmithKline plc (NYSE; LSE: GSK), had $1.1 billion in US sales in 2013.

Published by Globes [online], Israel business news - www.globes-online.com - on April 8, 2014

© Copyright of Globes Publisher Itonut (1983) Ltd. 2014

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018